ASCO 2022 Conference

ASCO 2022 CONFERENCE DELVEINSIGHT
A Quick Overview of Diffuse Large B-Cell
Lymphoma (DLBCL) at ASCO 2022
Diffuse Large B Cell Lymphoma is a deadly blood cancer that is the most frequent
kind of non-Hodgkin lymphoma (NHL), with over 40,000 new cases diagnosed in
Europe each year and another 25,000 in the United States.
While the ASCO 2022 annual meeting is approaching, pharma behemoths such as
Seagen, Hoffmann-La Roche, and others are seeking the opportunity to share
research on several cancers, including Diffuse Large B Cell Lymphoma.
Delveinsight has collated all of the future key abstracts while addressing a handful
of them, all while preserving a sense of brevity.
Abstract Number – 7500
Roche will discuss glofitamab's pivotal Phase II expansion data in patients with
R/R DLBCL Cancer. Will there be a follow-up to Polivy's first-in-class CD20xCD3 T-
cell engaging bispecific antibody?

Glofitamab is part of Roche's larger bispecific antibody development program,
which could lead to a new immunotherapy-based treatment option for a variety
of blood malignancies. According to recent data, 51.6 percent of patients
responded to glofitamab treatment, with 39.4 percent of these patients achieving
a complete response, the bulk of which (almost 78 percent) persisting for at least
12 months.
Apart from that, the findings suggest that glofitamab could be a good partner for
Roche's CD79b-directed ADC Polivy (Polatuzumab Vedotin), which was approved
in the EU earlier this week for previously untreated DLBCL and is expected to be a
USD 2 billion blockbuster. Based on these findings, glofitamab appears to have
the potential to provide a therapeutic benefit.
According to the above-mentioned positive outcomes, the upcoming pivotal
results are expected to be encouraging, bolstering the promise of glofitamab for
patients who have failed several prior lines of therapy and urgently require new
therapeutic alternatives. We eagerly await the results of the Phase II trial, which
will be presented as an oral abstract session at the ASCO Conference 2022, on
June 3, 2022.
Abstract Number - 7559
Seagen’s Adcetris (Brentuximab Vedotin), an antibody-drug conjugate for R/R
DLBCL
Seagen is about to present the Phase III ECHELON-3 study's safety and
effectiveness findings. ADCs are a promising class of immunotherapies that have
the ability to target tumour cells specifically while also improving the therapeutic
index of cytotoxic medicines. Because ADC efficacy and safety have progressed in
lockstep with developments in their design, the findings from the ECHELON-3
research will be presented as a poster session at the ASCO Meeting 2022 on June
4, 2022.
Conclusion
Glofitamab is one step closer to discovering a cure for people with heavily pre-
treated diffuse large B-cell lymphoma, which frequently relapses and becomes
more aggressive, thanks to new evidence. Furthermore, glofitamab's promise as a
new fixed-duration, readily available medication could be critical in improving

outcomes for those with this difficult-to-treat cancer who have few other options.
The most sought data for this cancer is the expansion results from the upcoming
Phase II trial in DLBCL. Apart from that, ADCs will play a critical role in the
treatment of patients with R/R DLBCL. As a result, it will be fascinating to follow
the outcomes of these two distinct classes of therapy.
To Get a Detailed analysis of ASCO Conference 2022 Abstracts, Visit: ASCO 2022
Detailed Coverage
Some of the Latest ASCO Abstract 2022 Launched:
 Can Breyanzi be a hit CAR-T in second-line treatment after failing in the
first-line setting for the patients with R/R Large B-cell lymphoma (LBCL)?
 Teclistamab, a soon-to-be-approved bispecific antibody, demonstrates its
promise in Multiple Myeloma during ASCO 2022.
 Merus’ Zenocutuzumab, a HER2-HER3 Bispecific Antibody, Successfully
Targets NRG1 Fusions in Lung and Pancreatic Cancer
Trending & Popular Healthcare Market Research Reports Given By DelveInsight
Parainfluenza Virus Infection Market
Parainfluenza Virus Infection Market Insights, Epidemiology, and Market Forecast-
2032" report deliver an in-depth understanding of the Parainfluenza Virus
Infection forecasted epidemiology.
Paranasal Sinus Cancer Market
Paranasal Sinus Cancer Market Insights, Epidemiology, Market Forecast report
delivers an in-depth understanding of the Paranasal Sinus Cancer epidemiology
Transient Ischemic Attack Market
DelveInsight's Transient Ischemic Attack Market Insights, Epidemiology, and
Market Forecast report delivers an in-depth understanding of the Transient
Ischemic Attack forecasted epidemiology
CAR-T Pipeline

CAR-T Pipeline Insights, 2022 report by DelveInsight outlays comprehensive
insights of present clinical development scenario and growth prospects across the
CAR-T market
Plaque Modification Devices Market
DelveInsight’s ‘Plaque Modification Devices -Market Insights, Competitive
Landscape and Market Forecast - 2027’ report delivers an in-depth understanding
of Plaque Modification Devices
Sarcopenia Market
DelveInsight's Sarcopenia Market Insights, Epidemiology, and Market Forecast-
2032" report delivers an in-depth understanding of the Sarcopenia, historical and
forecasted epidemiology
Hepatic Cirrhosis Market
DelveInsight's Hepatic Cirrhosis Market Insights, Epidemiology, and Market
Forecast report delivers an in-depth understanding of the Hepatic Cirrhosis,
historical and forecasted epidemiology
SGLT2 inhibitors Market
DelveInsight's SGLT2 inhibitors Market Insights, Epidemiology, and Market
Forecast report delivers an in-depth understanding of the SGLT2 inhibitors,
historical and forecasted epidemiology
Varicose Vein Treatment Devices Market
DelveInsight’s ‘Varicose Vein Treatment Devices -Market Insights, Competitive
Landscape and Market Forecast - 2027’ report delivers an in-depth understanding
of Varicose Vein Treatment
Brucellosis Market
Brucellosis Market Insights, Market Forecast report delivers an in-depth
understanding of the Brucellosis, historical and forecasted epidemiology, and the
Brucellosis market trends in 7MM.
Orthopedic Splints Market

DelveInsight’s ‘Orthopedic Splints -Market Insights, Competitive Landscape and
Market Forecast - 2027’ report delivers an in-depth understanding of Orthopedic
Splints..
Inflammatory Pain Market
Inflammatory Pain Market Insights, Epidemiology, and Market Forecast-2032
report deliver an understanding of the forecasted epidemiology, and the
Inflammatory Pain market trends in 7MM.
Testicular Neoplasm Market
DelveInsight's Testicular Neoplasm Market Insights, Epidemiology, and Market
Forecast report delivers an understanding of forecasted epidemiology and the
Testicular Neoplasm market trends in 7MM
Latest Healthcare Research Reports 2022 By DelveInsight
 B Cell Chronic Lymphocytic Leukemia Market
 Medical Marijuana Market
 Opioid-related Disorders Market
 Polycystic Kidney Disease Market
 UK Healthcare Outlook Report
 Urinary Catheters Market
 Coronary Microvascular Dysfunction CMD Market
 Sick Sinus Syndrome Market
 Oncolytic Virus Cancer Therapy Pipeline
 Pelvic Organ Prolapse Market
 B-Cell Maturation Antigen Targeted Therapies Market
 Asperger Syndrome Market
 Tuberculosis Market
 Sly Syndrome Market
 Membranous Nephropathy Market
 Proteus Syndrome Market
 Stem Cell Market
About Us

DelveInsight is a Business Consulting and Market research company, providing
expert business solutions for life science vertical and offering quintessential
advisory services in the areas of R&D, Strategy Formulation, Operations,
Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Contact Us
Yash
info@delveinsight.com

ASCO 2022 Conference

Recommended

Recommended

More Related Content

Similar to ASCO 2022 Conference

Similar to ASCO 2022 Conference (20)

More from DelveInsight Business Research

More from DelveInsight Business Research (20)

Recently uploaded

Recently uploaded (20)

ASCO 2022 Conference